A National Study Observing Lung Cancer Patients in Algeria to Understand Diagnosis, Treatment, and Outcomes

What this Trial Is About

Researchers are conducting a prospective, multicenter observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information on lung cancer patients in Algeria. This study focuses on various types of lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. The goal is to collect real-world data on the epidemiology, clinical features, pathology, molecular markers, and treatment patterns to improve lung cancer care nationwide. The study involves adult patients aged 18 years and older who have been diagnosed with lung cancer at the time of enrollment or within the prior 12 months. Participants are managed fully within oncology or pulmonology departments at 21 public and university hospitals across Algeria. Data are collected during routine clinical care visits without any additional study-specific procedures or interventions. Information such as tumor histology, molecular profiles, staging, and treatment choices are recorded securely in an electronic case report form. During the study, researchers will track clinical outcomes including treatment toxicities, response rates, progression-free survival, time to treatment discontinuation, and overall survival. Data collection aligns with standard care and includes demographic details, medical history, risk factors, and performance status. The study plans to enroll about 1,500 patients per year over 30 months, with each patient followed for at least 12 months to support future health planning and lung cancer management improvements in Algeria.

ALG-LungCancerRegistry (SAFRO2202)